Optimax Access’ Post

Exploring Health Technology Assessment in Key European Countries Discover how HTA frameworks vary across the UK, France, Germany, Spain, and Italy in our latest blog post. Each country uses unique approaches to assess and integrate new health technologies, impacting national healthcare policies and patient care. Key Insights: • UK’s NICE and France’s HAS: Driving cost-effectiveness and patient outcomes. • Germany and Spain: Focus on negotiated pricing models and regional adaptations. • Italy: Integrates HTA into regional healthcare to optimize resources. Learn more about the strategic role of HTA in shaping healthcare across Europe by reading the full article on our website. https://lnkd.in/eba8PACT #HEOR #reimbursement #costeffectiveness #pharmaceuticals #HTA #marketacces #HealthEconomics

Pharmaceutical Group of the European Union (PGEU) at the European Health Summit At today’s European Health Summit by the EBS, PGEU’s President, Aris Prins, participated in the panel 𝗥𝗲𝗶𝗺𝗮𝗴𝗶𝗻𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗦𝗲𝗹𝗳-𝗖𝗮𝗿𝗲 𝗶𝗻 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗪𝗲𝗹𝗹𝗯𝗲𝗶𝗻𝗴. The discussion highlighted self-care’s critical importance for patients’ access. #Pharmacists are central to this transformation, ensuring safe medication use and empowering individuals through #healthliteracy and digital tools. Key takeaways included: • Self-care integration: A cornerstone of efficient, #sustainable healthcare systems. • Relieving system pressures: Empowering citizens reduces strain on resources and professionals. • Combatting #AMR: Pharmacists lead in promoting responsible medicine use. • Collaboration and #innovation: Stakeholder partnerships and technology drive progress. By advancing self-care, we improve #accessibility, #affordability, and #resilience while empowering individuals to take control of their #health. #EHS2024

The journey to success is complex, but OPEN Health experts can provide the necessary roadmap. Explore key challenges in patient perspectives, healthcare, and pharma in our latest whitepaper and learn how to turn obstacles into opportunities. https://lnkd.in/epw9cBUH #HEOR #MedComms #PatientEngagement #GLP1

The journey to success is complex, but OPEN Health experts can provide the necessary roadmap. Explore key challenges in patient perspectives, healthcare, and pharma in our latest whitepaper and learn how to turn obstacles into opportunities. https://lnkd.in/epw9cBUH #HEOR #MedComms #PatientEngagement #GLP1

Want the inside track on #healthcare sector trends? Seeking expert guidance on today’s healthcare business challenges? Need to understand the nuances and dynamics of specific therapy areas…? Visit Ipsos’ new healthcare site today: https://lnkd.in/eRtGVAv4 Access our extensive library of data-led thought leadership, discover our world-leading insight, evidence and advisory solutions, or connect with a sector expert to learn how we can answer your healthcare business question. #Pharma #Medtech #RealWorldEvidence #MRx

The journey to success is complex, but OPEN Health experts can provide the necessary roadmap. Explore key challenges in patient perspectives, healthcare, and pharma in our latest whitepaper and learn how to turn obstacles into opportunities. https://lnkd.in/epw9cBUH #HEOR #MedComms #PatientEngagement #GLP1

In the Australian healthcare market, regulatory complexity remains one of the most significant hurdles for companies striving to bring life-saving innovations to patients. The rigorous approval processes and intricate compliance requirements are essential for ensuring safety and efficacy, but they can also delay access to critical therapies. This isn’t just a matter of bureaucracy—it's a matter of patient care and public health. The time it takes for a new treatment or medical device to navigate the regulatory landscape can mean the difference between life and death for patients in need. For companies, these delays can stifle innovation, increase costs, and create barriers to market entry. But the real impact is on patients who are left waiting for the therapies that could improve or even save their lives. Streamlining these processes doesn’t mean cutting corners on safety; it means finding a more efficient path to ensure that groundbreaking innovations reach those who need them most, without unnecessary delays. It’s about fostering a regulatory environment that encourages innovation while maintaining the highest standards of safety and efficacy. As industry leaders, we must collaborate with regulators, policymakers, and other stakeholders to advocate for a regulatory framework that is both rigorous and agile. This includes adopting new technologies, such as digital health tools, that can streamline compliance processes, as well as promoting greater transparency and communication between all parties involved. Together, we can work towards a more efficient regulatory landscape—one that not only upholds Australia’s high standards for healthcare but also accelerates the delivery of innovations to patients. Let’s lead the way in creating a regulatory environment that supports both innovation and patient care. How is your organisation navigating these regulatory challenges, and what changes do you believe are necessary to foster a more efficient approval process? Partner with Axis Health Co for the expertise and support needed to achieve your business objectives in Australia. Contact us at contactus@axishealthco.com to schedule a consultation.  #Pharma #medtech #biotech #commercialisation #Healthcare #Innovation #RegulatoryAffairs  Martin Hayes James Jones Daniel Thurley Kate Webb Nicholette (Nicky) Conway Vanessa Meikle

Delving into regulatory updates in Colombia at Biosimilars LatAm - Colombia 2024, Clara Sanchez, Advisor at ASCIF COLOMBIA highlighted the critical role of societal trust in acquiring health technologies. Join us in fostering trust and advancing healthcare accessibility! #BiosimilarsLatAm #regulatoryupdates #biosimilars #healthcareinnovation

Thinking brand-first or disease-first is the wrong start-point for healthcare digital platforms. According to VML Health’s Jason Gloye, enhancing these platforms in health requires focus on two key areas: patient partnerships and experience design. Read more: https://lnkd.in/e_3NZzVz #VMLHealth #PatientGroups #Healthcare #HealthcareMarketing #Pharma #PharmaMarketing

What is #HTA❓ #HealthTechnologyAssessment (HTA) is a systematic process that evaluates the value of health technologies, including tests, devices, medicines, vaccines, procedures, and healthcare delivery systems. HTA uses explicit methods to determine the: 📌 clinical effectiveness, 📌 safety, 📌 cost-effectiveness, and broader impact of these technologies. The primary purpose of HTA is to inform decision-making and promote equitable, efficient, and high-quality health systems. Proper assessment and the careful selection of new technologies are crucial steps in the #DIGI4Care project, in which the Digital Health and Innovation Cluster Bulgaria is participating. 🌱 And after all: Why Does HTA Matter? Swipe right to find out.👉 #DiGi4Care #ClinicalEffectiveness